SI-BONE (NASDAQ:SIBN) has announced the first in-patient procedures using its iFuse TORQ TNT Implant System (TNT), designed to address anatomic and biomedical challenges of pelvic fragility fractures as opposed to...
Jefferies launched coverage of SI-BONE (NASDAQ:SIBN) with a “buy” rating and $20 price target. The stock closed at $15.71 on Oct. 11. SI-BONE is the current market and innovation leader in sacropelvic spine surgery...
Cantor Fitzgerald analyst Ross Osborn assumed coverage of SI-BONE (NASDAQ:SIBN) with an “overweight” rating and price target of $34. The stock closed at $21.28 April 6. SI-BONE is a medical device company that...